Table 1.
Cohort Description | Group | N | Treatment | 30 Day DFP Exposure Period Procedure/Testing Days | 14 Day Drug-Free Washout Period Procedure/Testing Days | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Behavioral Cohort | Grip Strength | Open Field | Rotarod | Grip Strength | Open Field | Rotarod | NOR | WM | PPI | |||
A | 26 | VEH | 7,14,21,28 | 8,22 | 16,30 | 35,42 | 37 | 34,44 | 33-37 | 38-44 | 41-43 | |
B | 26 | DFP 0.25 | 7,14,21,28 | 8,22 | 16,30 | 35,42 | 37 | 34,44 | 33-37 | 38-44 | 41-43 | |
C | 15 | DFP 0.5 | 7,14,21,28 | 8,22 | 16,30 | 35,42 | 37 | 34,44 | 33-37 | 38-44 | 41-43 | |
D | 19 | DFP 0.75 | 7,14,21,28 | 8,22 | 16,30 | 35,42 | 37 | 34,44 | 33-37 | 38-44 | 41-43 | |
E | 11 | DFP 1.0 | 7,14,21,28 | 8,22 | 16,30 | 35,42 | 37 | 34,44 | 33-37 | 38-44 | 41-43 | |
Blood Draw | Blood Draw | |||||||||||
Plasma Cohort | A | 4 | VEH | 0,7,14,21,30 | 37, 44 | |||||||
B | 4 | DFP 0.25 | 0,7,14,21,30 | 37, 44 | ||||||||
C | 4 | DFP 0.5 | 0,7,14,21,30 | 37, 44 | ||||||||
D | 4 | DFP 0.75 | 0,7,14,21,30 | 37, 44 | ||||||||
E | 4 | DFP 1.0 | 0,7,14,21,30 | 37, 44 | ||||||||
Sacrifice | ||||||||||||
Brain AChE & ChAT Cohort 1 | A | 4 | VEH | 30 | ||||||||
B | 4 | DFP 0.25 | 30 | |||||||||
C | 4 | DFP 0.5 | 30 | |||||||||
D | 4 | DFP 0.75 | 30 | |||||||||
E | 4 | DFP 1.0 | 30 | |||||||||
Sacrifice | ||||||||||||
Brain AChE & ChAT Cohort 2 | A | 4 | VEH | 37 | ||||||||
B | 4 | DFP 0.25 | 37 | |||||||||
C | 4 | DFP 0.5 | 37 | |||||||||
D | 4 | DFP 0.75 | 37 | |||||||||
E | 4 | DFP 1.0 | 37 | |||||||||
Brain AChE & ChAT Cohort 3 | A | 4 | VEH | Sacrifice | ||||||||
B | 4 | DFP 0.25 | 44 | |||||||||
C | 4 | DFP 0.5 | 44 | |||||||||
D | 4 | DFP 0.75 | 44 | |||||||||
E | 4 | DFP 1.0 | 44 |
VEH, vehicle; DFP, diisopropylfluorophosphate; NOR, novel object recognition, WM, water maze, PPI, prepulse inhibition; ChAT, choline acetyltransferase, AChE, acetylcholinesterase